Soft-Robotic Rehab Devices Draw €2.95M Series A
Rehabilitation operators and hospital procurement teams should watch whether these FDA-listed tools expand into home and multi-setting care.
Updated on Nov. 6, 2026 in Healthcare

Edinburgh- and Boston-based Bioliberty raised a €2.95 million ($3.3 million) Series A extension, with TGH Ventures, Ballad Ventures, Whiterock and 25m Health joining as new institutional backers. The soft-robotic rehabilitation developer's total funding now stands at €12.07 million ($13.5 million) for operators in the healthcare technology and rehabilitation sector.
Why it matters
The round brings institutional capital into a company whose hardware is already FDA-listed and commercially launched in the United States, signaling investor confidence in rehabilitation technology that is moving from clinical study into routine care. For healthcare operators, it marks a shift in which rehabilitation tools are being built around inpatient facilities and then extended toward outpatient and home use.
The extension lifts Bioliberty's total funding to €12.07 million ($13.5 million), with the prior rounds accounting for €9.12 million ($10.2 million) of that total. Four new institutional backers joined the Series A extension, which the company says can start therapy sessions in under five minutes.
The players
Bioliberty
A rehabilitation technology developer headquartered in Edinburgh with a Boston presence, building soft-robotic devices for upper-extremity recovery and selling them into hospital and clinical settings.
TGH Ventures
The investment arm of Tampa General Hospital, one of the largest health systems in Florida, that now backs Bioliberty as a new institutional investor.
Mount Sinai
A large New York health system that ran a 2024 clinical study with Bioliberty, giving the company a documented U.S. hospital evaluation partner.
The details
Bioliberty develops soft-robotic rehabilitation technology aimed at upper-extremity recovery, with products including Lifehub and Lifeglov that are FDA-listed in the United States. The technology was co-developed with inpatient rehabilitation facilities, which the company cites as the basis for its clinical design. The new capital is earmarked for extending the technology into the home, connecting rehabilitation data across care settings, and building AI capabilities for clinical decision-making.
Timeline
2020: Bioliberty is founded by four Northern Ireland co-founders.
2024: The company conducts a clinical study with the Mount Sinai health system.
2025: Bioliberty launches commercially in the United States.
Market Landscape
The round places Bioliberty among a growing set of rehabilitation technology developers that have moved from clinical study into FDA-listed commercial products. Its Lifehub and Lifeglov devices give it a regulatory position in the U.S. market that the new institutional backers are being asked to help scale.
Operators in rehabilitation and physical therapy should watch for hospital-developed rehabilitation tools expanding into outpatient and home settings, which could change referral patterns and equipment purchasing. Procurement and clinical leads evaluating upper-extremity devices may want to track the company's home-use and data-integration rollout as it arrives.
The takeaway
The round signals that investors are backing rehabilitation hardware that has already cleared FDA listing and reached U.S. hospitals, not only early-stage concepts. Operators can file the company's future home-use and data-integration announcements as indicators of whether hospital-grade rehabilitation is moving into lower-cost care settings.
Further reading
For broader context on how medical technology companies are financed and scaled, explore our Healthcare coverage.
Source note: This article includes information reported by EU-Startups.


